Scilex Holding Company (SCLX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.87 (+1.08% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SCLX ranks #470 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).
Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 12.2% FCF Margin ($3.7M FCF) & 415.8% Gross Margin
SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (-0.40% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While SCLX currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.02) and Max Pain ($1.96) forces dealer call-delta covering toward $17.65.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Scilex Holding Company (SCLX) advanced +1.08% to $1.87, trading at 2% of its 52-week range ($1.83 – $16.81). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
Its restatement takes every reported bitcoin off the books, including 837 BTC Scilex agreed to buy in June. No definitive deal has been disclosed.
Datavault AI says it has been unable to withdraw its Bitcoin from Biconomy since June and will restate four financial reports tied to a $150 million Scilex deal.
A $150 million Bitcoin deal left Datavault AI unable to reach its coins. Its stock lost half its value. What happened?
Crypto treasury firm Datavault AI (NASDAQ: $DVLT) says it is unable to access a large portion of its Bitcoin (CRYPT...
Datavault AI shares plunge nearly 40% after invalidating financial statements tied to a $150M Bitcoin deal.
* Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.
DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their outstanding shares is
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #470 by composite RQD confidence (40/100, grade D-) and #849 by equity capitalization ($15.7M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SCLX
ACTIVE
Scilex Holding Company | D- | 40/100 | — | 96.0% | -35.0% | +1.08% | $15.7M | Benchmark Subject |
| DYAI Dyadic International Inc. | E | 31/100 | — | 24.9% | -35.0% | -1.10% | $15.2M | /dyai-vs-sclx → |
| ABOS Acumen Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | +14.09% | $15.2M | /abos-vs-sclx → |
| PLUR Pluri Inc. | E | 34/100 | — | 49.0% | -35.0% | -3.23% | $16.7M | /plur-vs-sclx → |
| JSPR Jasper Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -2.35% | $17.3M | /jspr-vs-sclx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $30.3M | -$374.1M | $3.8M | $3.7M | $365.0M | — |
| FY2024 (FY) | 2024-12-31 | $56.6M | -$72.8M | $19.3M | $19.3M | $93.0M | — |
| FY2023 (FY) | 2023-12-31 | $46.7M | -$114.3M | -$20.7M | -$20.7M | — | — |
As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.87 (+1.08% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SCLX ranks #470 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).
Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
SCLX last traded at $1.87 (+1.08% on volume of 54,938 shares), positioning the stock -53.48% below its 50-day simple moving average ($4.02) and -64.45% below its 200-day simple moving average ($5.26). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 0.3% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.64 to $2.10).
Scilex Holding Company (SCLX) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.87 (+1.08% 1D, market capitalization $15.7M).
Scilex Holding Company (SCLX) is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances)..0B on a rounded basis, while the market data reports $17.5M. — describes its products, customers, or revenue model. The source data reports gross margin of 96% alongside operating margin of -60%, indicating a high gross-margin structure with operating losses below that line.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scilex Holding Company (SCLX) reported $30.3M in annual revenue (up from $56.6M in FY2024, -46.5% YoY) and -$374.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.7M revenue, -$114.3M net income) through FY2025, SCLX scaled operating cash flow to $3.8M and free cash flow to $3.7M, backed by $365.0M in total assets against $0 in total debt.
Sector classification is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances). — identifies upstream suppliers, downstream customers, or sector correlations. Because no dependency links are present, second-order bottlenecks cannot be mapped from the source data.
Real-time company headlines, analyst actions, and sector developments for Scilex Holding Company (SCLX) • Click "Debate This Headline" to argue it in the Roar Pit below
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
Its restatement takes every reported bitcoin off the books, including 837 BTC Scilex agreed to buy in June. No definitive deal has been disclosed.
Datavault AI says it has been unable to withdraw its Bitcoin from Biconomy since June and will restate four financial reports tied to a $150 million Scilex deal.
A $150 million Bitcoin deal left Datavault AI unable to reach its coins. Its stock lost half its value. What happened?
Crypto treasury firm Datavault AI (NASDAQ: $DVLT) says it is unable to access a large portion of its Bitcoin (CRYPT...
Datavault AI shares plunge nearly 40% after invalidating financial statements tied to a $150M Bitcoin deal.
* Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.
DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its
The 21.05% FCF yield signals cash generation relative to the $2.06 share price despite negative earnings.. When you look under the hood at SCLX, Fundamental Cash Engine is 12/20 with 96.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $16.81. My 12M target is $2.35.
@DeepValue_CFA Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.85 and keeping dry powder in case we test $1.72.
A -35% ROIC and a -60% net margin, with FY 2025 net loss of -$374.1M against $5.0M cash, leave the balance sheet highly vulnerable.. Look at the math on SCLX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $1.63 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).